Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News HCW Biologics Inc HCWB

Healthcare Biotechnology
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat... see more

Recent & Breaking News (NDAQ:HCWB)

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 - 25, 2022

GlobeNewswire May 23, 2022

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewswire May 13, 2022

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI(TM) Platform At the 105th Annual Meeting of the American Association of Immunologists

GlobeNewswire May 5, 2022

HCW Biologics' CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022

GlobeNewswire April 19, 2022

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

GlobeNewswire March 28, 2022

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

GlobeNewswire March 24, 2022

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein

GlobeNewswire January 24, 2022

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

GlobeNewswire January 20, 2022

HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conference 2022

GlobeNewswire January 19, 2022

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 - 13, 2022

GlobeNewswire January 6, 2022

HCW Biologics' Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year

GlobeNewswire December 13, 2021

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

GlobeNewswire November 12, 2021

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer

GlobeNewswire October 28, 2021

HCW Biologics Announces Appointment of Two New Members to Board of Directors

GlobeNewswire October 27, 2021

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic

GlobeNewswire August 24, 2021

HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI(TM)) Discovery Platform

GlobeNewswire August 17, 2021

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

GlobeNewswire August 13, 2021

HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering

GlobeNewswire July 22, 2021

HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering

GlobeNewswire July 19, 2021

Podcasts